Aer Therapeutics’ 90 mg fexlamose trial fails COPD efficacy endpoints
AI Summary- Aer Therapeutics reported that its Phase 2a fexlamose COPD study missed primary and secondary efficacy endpoints.
- 119 patients received daily nebulized 90 mg fexlamose or placebo in the AER-01-002 study.
- Fexlamose produced more respiratory adverse events and treatment discontinuations than placebo.